In a study led by van Laarhoven and collaborators, five critically ill COVID-19 patients with severe defects in cellular immune responses, high SARS-CoV-2 viral RNA loads, and no respiratory improvement were treated with IFN-γ (100 μg subcutaneously, thrice weekly). The gene discussed is IFNG; the disease is COVID-19.